DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Will Bioresorbable Vascular Stents Overtake Drug-Eluting Stents As The Gold Standard In CAD Treatment?

By Sean Messenger, Megha Maheshwari, Swarnadip Dutta, and Harsh Parikh

Thank you for your interest in Will Bioresorbable Vascular Stents Overtake Drug-Eluting Stents As The Gold Standard In CAD Treatment? Please fill out the form below to access your whitepaper.